Chemotherapy News and Research

Latest Chemotherapy News and Research

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.

24 Mar 2010

Bioalliance Pharma's anti-emetic drug Setofilm receives European approval

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced approval for Setofilm® in 16 European countries.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Report shows growth of the U.S. market for vascular access devices and accessories

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for vascular access devices and accessories was valued at just over $3 billion in 2009 and is estimated to reach over $4.6 billion by 2016.

23 Mar 2010

More awareness and earlier diagnosis of brain cancer needed

One of the UK’s largest surveys of brain cancer sufferers and carers, conducted by the Samantha Dickson Brain Tumour Trust, suggests that GPs and the general public need better guidance on spotting the key symptoms to aid earlier diagnosis and improve survival.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

Short of specialists and cancer care

Associate Professor Bogda Koczwara, from the Medical Oncology Group of Australia, conducted the survey which found just 19 per cent of all those diagnosed with cancer were receiving chemotherapy.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it completed financing in which the company raised $15.5 million.

23 Mar 2010

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two of fifteen treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

23 Mar 2010

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Investment report on Gentium from InvestorSoup.com

InvestorSoup.com announces an investment report featuring Gentium SpA. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

22 Mar 2010

StockPreacher.com releases investment report on A.P. Pharma

StockPreacher.com announces an investment report featuring A.P. Pharma Inc. (Nasdaq:APPA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

22 Mar 2010

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.

22 Mar 2010

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Today, Formatech, Inc. announces the selection of Tracon Pharmaceuticals’ TRC102 clinical product as the next Fillanthropy™ Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon’s upcoming clinical trials.

22 Mar 2010

Scientists identify new growth factor that stimulates expansion of hematopoietic stem cells

Scientists at Duke University Medical Center have identified a new growth factor that stimulates the expansion and regeneration of hematopoietic (blood-forming) stem cells in culture and in laboratory animals. The discovery, appearing in the journal Nature Medicine, may help researchers overcome one of the most frustrating barriers to cellular therapy: the fact that stem cells are so few in number and so stubbornly resistant to expansion.

22 Mar 2010

Susan G. Komen receives $31,680 as donation for the Cure, San Diego

The Associates of AimLoan.com, a San Diego based Internet Direct Lender, announced a generous donation to Susan G. Komen for the Cure, San Diego for a total of $31,680. This contribution positions the organization as the second largest corporate donor in San Diego. The donation is a result of their 4th Quarter 2009 Community Service Website Campaign.

20 Mar 2010

Research roundup: Insurance crisis tough on middle class; Hospitals' profit margins on private patients up

Private-Payer Profits Can Induce Negative Medicare Margins - "Hospitals' profit margins on privately insured patients have risen dramatically in recent years, while profit margins on Medicare patients have fallen," write the authors, who all work for MedPAC.

20 Mar 2010

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.

19 Mar 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Bioalliance Pharma's anti-emetic drug Setofilm receives European approval

Renowned leaders to discuss latest findings in early-stage drug development for cancer

Report shows growth of the U.S. market for vascular access devices and accessories

More awareness and earlier diagnosis of brain cancer needed

ChemGenex shares falter as FDA requests more data on new leukemia drug

Short of specialists and cancer care

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Nodality raises $15.5M to support launch of acute myelogenous leukemia test

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Investment report on Gentium from InvestorSoup.com

StockPreacher.com releases investment report on A.P. Pharma

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Scientists identify new growth factor that stimulates expansion of hematopoietic stem cells

Susan G. Komen receives $31,680 as donation for the Cure, San Diego

Research roundup: Insurance crisis tough on middle class; Hospitals' profit margins on private patients up

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in